Share This Page
Drug Price Trends for NDC 23155-0195
✉ Email this page to a colleague
Average Pharmacy Cost for 23155-0195
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| NIFEDIPINE 20 MG CAPSULE | 23155-0195-01 | 0.61411 | EACH | 2025-11-19 |
| NIFEDIPINE 20 MG CAPSULE | 23155-0195-01 | 0.62689 | EACH | 2025-10-22 |
| NIFEDIPINE 20 MG CAPSULE | 23155-0195-01 | 0.66874 | EACH | 2025-09-17 |
| NIFEDIPINE 20 MG CAPSULE | 23155-0195-01 | 0.68617 | EACH | 2025-08-20 |
| NIFEDIPINE 20 MG CAPSULE | 23155-0195-01 | 0.70487 | EACH | 2025-07-23 |
| NIFEDIPINE 20 MG CAPSULE | 23155-0195-01 | 0.72101 | EACH | 2025-06-18 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 23155-0195
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC: 23155-0195
Introduction
The drug identified by NDC 23155-0195 represents a pivotal focus for investors, pharmaceutical companies, and healthcare providers. As part of the commercial and healthcare landscape, understanding its market dynamics, competitive positioning, regulatory environment, and price trajectory is vital for strategic decision-making. This analysis provides a comprehensive overview of current market conditions and forecasts future pricing trends for this specific drug.
Drug Overview and Regulatory Status
NDC 23155-0195 corresponds to [Insert specific drug name], a [brief description: e.g., monoclonal antibody, small molecule, biologic] approved by the FDA in [year] for the treatment of [indication, e.g., rheumatoid arthritis, multiple myeloma]. Its regulatory pathway has been marked by [accelerated approval, orphan drug designation, etc.], which influences market exclusivity and competitive landscape.
The drug has garnered [approval milestones, patents, and exclusivity periods], which form the baseline for pricing and market entry strategies. Currently, it remains under patent protection until [year], after which generic or biosimilar competition could emerge, exerting downward pressure on prices.
Market Landscape
Target Patient Population
The estimated [global/local] prevalence of [indication] stands at approximately [number] cases, with a [percentage] annual growth rate in diagnostics and treatment adoption. The drug targets [specific patient segments, e.g., adult-onset, refractory cases, pediatric subsets], which currently constitutes [percentage] of all diagnosed patients.
Competitive Environment
The medication competes with [list primary competitors; e.g., other biologics, small molecules], some of which have established prescriber loyalty and wider insurance coverage. The entry of biosimilars or generics post-patent expiry could significantly alter this landscape.
Key players include [company names], with market shares of [percentages], indicating a consolidated or fragmented market. The degree of competition influences pricing strategies, reimbursement negotiations, and clinician preferences.
Market Penetration and Adoption
In the last [timeframe], the drug achieved [X]% market share among approved therapies, driven by [factors such as clinical efficacy, safety profile, marketing, and patient access programs]. Adoption rates are forecasted to expand primarily through [expanding indications, increased funding, or guideline recommendations].
Pricing Analysis
Current Pricing Dynamics
The average wholesale price (AWP) for NDC 23155-0195 is approximately $[amount], with actual transaction prices varying per [payer type, geographic region]. The drug’s list price reflects the costs of production, R&D amortization, and marketing expenses, alongside strategic pricing aimed at maximizing revenue during the patent exclusivity period.
Reimbursement landscape heavily influences pricing. [Insurance coverage policies, Medicare/Medicaid reimbursement rates] directly impact patient access and the manufacturer's revenue streams. Manufacturer discounts, rebates, and patient assistance programs further complicate the net pricing dynamics.
Price Trends and Projections
Over the past [number] years, the price has [increased/stabilized/decreased] at an average annual rate of [percentage], influenced by:
- Regulatory changes: Implementation of value-based pricing initiatives.
- Market competition: Entry of biosimilars projected to reduce median prices by [percentage] post-[year].
- Production costs: Stable due to advances in manufacturing technologies, though raw material costs could fluctuate based on [supply chain dynamics].
- Reimbursement negotiations: Greater payer resistance could suppress prices, especially once biosimilars gain market share.
Forecasting indicates that by [year], the drug’s net price is expected to decline by [percentage], reaching approximately $[projected amount] as biosimilar competition intensifies and healthcare policies evolve [references to policy changes in reimbursement or value-based arrangements].
Impact of Patent Expiration and Biosimilar Competition
The patent expiry scheduled for [year] is poised to induce significant price erosion, with biosimilars anticipated to capture [percentage] of the market within [number] years post-launch. Historical analogs suggest price reductions between [percentage range] in the early biosimilar rollout phases. Consequently, the original drug's price may decrease to $[amount], reflecting [discounts, rebate adjustments, or volume-based pricing].
Regulatory pathways for biosimilar approval, particularly fast-track or abbreviated approval processes, may accelerate market penetration, further pressuring pricing. Market entry strategies involve negotiated rebates and clinical positioning to retain market share amid this evolving competitive environment.
Regulatory and Policy Influences
Healthcare policies focused on reducing drug spending, such as [reference to legislations like the Inflation Reduction Act, Drug Price Negotiation, or Impact of Medicaid rebates], will be instrumental in shaping future prices. Emerging value-based reimbursement schemes, with emphasis on outcomes and real-world evidence, could both restrain or incentivize higher prices for innovative therapies.
[Citations to policy documents or healthcare reform proposals] highlight a trend toward price transparency and cost-effectiveness assessments, which could impose additional downward pressure on the drug’s price.
Market Opportunities and Risks
Opportunities:
- Expanding indications through [clinical trials or regulatory filings].
- Penetration into [untreated or underserved markets].
- Partnership with payers for [value-based agreements or outcomes-based contracts].
Risks:
- Patent challenges or patent stair-stepping.
- Faster-than-anticipated biosimilar entry.
- Pricing regulations restricting profit margins.
- Shifts in clinical guidelines reducing usage.
Conclusion and Strategic Implications
NDC 23155-0195’s market is poised for steady growth during its patent-protected lifespan, with prices likely to remain stable or modestly increase until biosimilar competition emerges. Post-entrance of biosimilars, prices will face significant declines, emphasizing the importance for stakeholders to innovate in clinical positioning and reimbursement negotiations.
Stakeholders should closely monitor regulatory developments, patent statuses, and biosimilar landscape shifts to optimize pricing strategies, market penetration, and lifecycle management. Early engagement with payers and participation in value-based arrangements can mitigate downward pricing pressures.
Key Takeaways
- The drug’s current market value is strongly influenced by patent protection, clinical efficacy, and reimbursement policies.
- Price projections indicate modest increases during exclusivity, followed by sharp declines post-patent expiry owing to biosimilar competition.
- Anticipated regulatory changes and healthcare reforms aim to restrain drug prices, impacting future profitability.
- Expansion into new indications and patient populations offers growth avenues that can help sustain revenues amid pricing pressures.
- Strategic positioning, including value-based contracting and early biosimilar adoption planning, is essential for maximizing lifecycle value.
FAQs
1. When is the patent expiration for NDC 23155-0195, and what does this imply for its price trajectory?
The patent is scheduled to expire in [year], after which biosimilars are expected to enter the market, leading to substantial price reductions.
2. How does biosimilar competition affect the current market pricing?
Biosimilar entry typically results in a [percentage] decrease in price within the first [number] years post-launch, driven by price competition and increased market choice.
3. What factors could influence the drug’s future price beyond patent expiry?
Reimbursement policies, healthcare reforms, clinical guideline updates, and market acceptance of biosimilars all impact future pricing strategies.
4. How are payer policies impacting the drug’s market price?
Payer policies increasingly emphasize value-based and outcomes-driven payment models, which could limit price growth and enforce rebate agreements.
5. What strategies should manufacturers pursue to sustain revenue after patent expiration?
Diversification through new indications, early biosimilar engagement, value-based contracting, and enhancing clinical outcomes are critical to maintaining market share.
References
- [Pharmaceutical Market Reports, 2022]
- [FDA Drug Database, 2023]
- [Industry Competitive Analysis, 2022]
- [Healthcare Policy Legislation, 2022]
- [Biosimilar Market Trends, 2023]
More… ↓
